Reference: GILA/ID/AUD-027/AGCHEM
Board seat: Independent Director, Non-Executive
Primary board location: Mumbai with formulation-plant and field-channel visits
Meeting model: Six Audit meetings, four board meetings and seasonal reviews
Mandate type: Audit Committee Chair & Financial Expert
Status: Confidential live-search specification; client identity released only after conflict clearance and NDA.
The anonymised enterprise
A listed crop-protection company manufacturing formulations and technical products, with branded domestic distribution and regulated exports.
Revenue is ₹3,000–4,200 crore. Inventory seasonality, channel schemes, product registrations and export receivables create judgement around cut-off, obsolescence and provisions.
The board problem and strategic reason for appointment
The board seeks an Audit Chair who can connect financial reporting to product stewardship. Channel loading, expired inventory, registration impairment and distributor credit cannot be reviewed as separate problems.
The board is not buying a credential. It is appointing an independent decision-maker who can convert this problem into a governed sequence of choices, evidence and accountability. Success will be judged by the quality of decisions and control improvement, not by the number of recommendations made.
Board position, authority and interfaces
Audit Committee Chair; member of Risk/Sustainability; direct access to stewardship, legal and internal audit leaders.
The appointee will have direct, unfiltered access to the Company Secretary and to the relevant control-function leaders. Any advisory support requested by the board must remain management-executed: the director sets questions, tolerances and evidence standards, but does not become an executive or consultant.
First 12–18 month strategic charter
- Test sales cut-off, returns and channel inventory by crop season and geography; review slow-moving and registration-dependent inventory impairment; challenge capitalised registration dossiers, data-rights lives and cancellation triggers; reconcile stewardship complaints, product recalls and distributor-credit decisions to financial provisions
- Reset the Audit Committee agenda around judgement-heavy accounting, cash conversion, control exceptions, related parties, audit quality and closure evidence instead of receiving compliance presentations.
- Establish private sessions with the statutory auditor, internal auditor, CFO and whistleblower function; define escalation triggers and protect the independence of each control function.
Decision profile sought
Essential evidence
- Audit partner, CFO or finance leader with agrochemical, pharma, chemicals or seasonal distribution depth; listed Audit Chair capability; inventory and intangible-asset judgement
Differentiators
- Product registration or export-market exposure; experience detecting channel loading or distributor side agreements
GILA will assess audit-chair temperament, forensic curiosity, accounting depth relevant to the business model, and the courage to slow a transaction or close when evidence is weak. Candidates should expect a case discussion based on an ambiguous board decision from this mandate, not a career-history interview alone.
Independence, suitability and downside diligence
The search will apply Section 149(6), Sections 164–165, Schedule IV and the applicable listing or sector rules to the entity’s legally verified status at the appointment date. Databank/proficiency status, listed-entity directorship and committee ceilings, pecuniary relationships, relatives’ interests, recent audit/advisory work and interlocking directorships will be checked. The appointment is subject to formal legal and secretarial confirmation; this posting is not a substitute for that determination.
Mandate-specific screens: Distributor, formulation vendor, registration consultant or competing brand relationships; recent statutory audit/advisory work; agricultural land interests tied to trials.
Before accepting the seat, the candidate will receive under NDA the latest board composition, committee charters, material litigation/regulatory schedule, related-party map, last audited accounts, current D&O policy and the specific risk papers necessary to make an informed liability assessment.
Twelve-month outcomes
The board expects an Audit Committee that can explain the economic substance behind the numbers and prove that exceptions were closed, not narrated away. For this particular seat, the evidence will be:
- Channel inventory and returns independently visible; registration and inventory impairments use controlled triggers; stewardship events flow promptly into provisions and disclosures
Commitment, protection and economics
- Expected load: 22–28 days annually, seasonally concentrated.
- Terms: Five-year term; Audit Chair fee; product-liability, environmental and D&O cover.
- Protection: Appointment letter, deed of indemnity where legally available, appropriate D&O cover including discovery/run-off terms, access to independent advice under the board-approved protocol, and complete minuting of dissent.
- Equity: No stock options where the appointment is legally an independent-director seat subject to Section 149(9). Any private-company structure outside that perimeter will be expressly classified and separately advised; no equity is implied by this posting.
Search process
Conflict pre-clearance → GILA/SYMPHONY™ board-fit interview → mandate case → document-led diligence under NDA → references from board peers and control functions → NRC/owner interviews → statutory, regulatory and reputation checks → board recommendation. Candidate consent, disclosures and appointment approvals will follow the law and the entity’s constitutional documents.